Do you want to read an article? Please log in or register.
Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations
Genitourinary Cancer
Related content
Genitourinary Cancer
(177)Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study
Eur J Cancer
Mandel P, Groener D, Follacchio G, Ürün Y, Bourlon MT, Sabet A, Grünwald F, Tural D, Büttner T, Kopp RM, Taha T, Chun FK, Facchini G, Myint ZW, Seront E, Conteduca V, Quiroga MNG, Aurilio G, Palacios GA, Bögemann M, Roviello G, Matrana MR, Sammarco E, Laguado MIZ, Galli L, Ansari J, Danielli L, Molina-Cerrillo J, Rescigno P, Yazgan SC, Bastos DA, Jazieh AR, Monteiro FSM, Soares A, Massari F, Wenzel M, Capoccetti F, Santoni M
doi: 10.1016/j.ejca.2025.115789
Genitourinary Cancer
Non-Cancer Causes of Death in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Analysis
Prostate
Garcia de Herreros M, Rodrigo C, Ferrer-Mileo L, Fernández-Mañas L, Mases J, Diaz N, Vilaseca A, Altamirano M, Gibanel R, Ribal MJ, Jimenez N, Reig O, Figols M, Climent MÁ, Font A, Mellado B
doi: 10.1002/pros.70174
Genitourinary Cancer
Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-resistant Prostate Cancer
Clin Cancer Res
Jani CT, Tran E, Zhang N, Tsai J, Dong J, Bucheit L, Pan E, Panian J, Chen YW, McKay RR
doi: 10.1158/1078-0432.CCR-25-3071
Genitourinary Cancer
Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
Lancet Oncol
Fizazi K, Morris MJ, Shore ND, Chi KN, Crosby M, de Bono JS, Herrmann K, Roubaud G, Nagarajah J, Fleming M, Lewis B, Nordquist L, Carnahan N, Ghebremariam S, Hertelendi M, Castellano D, Sartor O
doi: 10.1016/S1470-2045(25)00189-5
Lung, Respiratory and Thoracic Cancer
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study
Lung Cancer
Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y
doi: 10.1016/j.lungcan.2025.108748
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV
doi: 10.1016/j.esmoop.2025.106031
Genitourinary Cancer
Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany
Prostate Cancer Prostatic Dis
Sondermann M, Stehr A, Hirtsiefer C, Menzel V, Buttmann-Schweiger N, Flemming PW, Kraywinkel K, Thomas C, Boehm K
doi: 10.1038/s41391-026-01092-w
Genitourinary Cancer
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study
Prostate Cancer Prostatic Dis
Büttner T, Rizzo M, Bernal Vaca L, Molina-Cerrillo J, Alonso-Gordoa T, Juárez A, Buchler T, Seront E, Kucharz J, Gandur Quiroga MN, Bourlon MT, Bögemann M, Kopecky J, Rescigno P, Fiala O, Rodriguez-Vida A, Myint ZW, Ürün Y, Scagliarini S, Poprach A, Matthews D, Li H, Rizzo A, Mosca A, Lenci E, Melichar B, Wenzel M, Mandell P, Massari F, Antonarakis ES, Santoni M
doi: 10.1038/s41391-025-01067-3
Genitourinary Cancer
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis
Prostate Cancer Prostatic Dis
Yu EY, Suzuki H, Pieczonka CM, Gotto G, Briganti A, Luz M, Murphy D, Malone R, Hamilton J, Chan JE, Sieber P, Given RW, Hellmis E, Kretz T, Spiegelhalder P, Gómez-Caamaño A, Amela YM, Artignan X, Uemura H, Fujita N, Adorjan P, Ghadessi M, Verholen F, Armstrong AJ
doi: 10.1038/s41391-025-01047-7